(Reuters) - Celgene Corp, which said it would buy Juno for $9 billion earlier this week, reported a quarterly loss on Thursday, hurt by a $1.21 billion income tax charge.
The U.S. biotechnology company posted a net loss of $81 million, or 10 cents per share, in the fourth quarter ended Dec. 31, from a profit of $429 million, or 53 cents per share, a year earlier.
Revenue rose to $3.48 billion from $2.98 billion.
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Martina D'Couto)
Disclaimer: No Business Standard Journalist was involved in creation of this content
